Wednesday, August 19, 2020 1:25:27 PM
Sorrento’s Test Is Much More Useful
The test could also be used to screen individuals for the virus before they enter hospitals, office buildings, and trains. People entering those facilities would just have to arrive at their destinations 30 minutes to an hour early, take the test, (which would be administered by someone with personal protective equipment) and then come back. At that point, it will have been determined whether they have the virus, and the organizations could act accordingly.
Obviously, arriving just a half hour to an hour early is much more practical in many cases than having to arrive a few hours early. Getting to a restaurant, sporting event, train station, hospital or an office an hour early and then needing to wait for an hour is (in most cases) not that much of an inconvenience. Conversely, having to arrive at those places even a few hours early is terribly inconvenient and sometimes not at all practical.
The Bottom Line on SRNE Stock
Given its superior convenience and the advantages it gives to many enterprises, Sorrento’s test could very easily proliferate around the world over the next six to eight months. Further, I still believe that the company’s therapies for the coronavirus could be used to treat patients by the end of this year. As a result, I like the shares at this point.
Larry Ramer has conducted research and written articles on U.S. stocks for 13 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been Roku, oil stocks and Snap. You can reach him on StockTwits at @larryramer. As of this writing, he owned shares of Sorrento.
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM
- Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the A • GlobeNewswire Inc. • 06/05/2023 01:00:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM